#POLB Poolbeg Pharma PLC – Immunomodulator I Patent Portfolio Strengthened September 20, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

20 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has received a notice of allowance from the Japanese Patent Office in relation to its Immunomodulator I patent application.   The claims deemed allowable cover a p38 MAPK (mitogen-activated protein kinase) inhibitor for use in the treatment of severe influenza in human patients and strengthens the Company’s robust intellectual property…

Continue reading